Intuitive Surgical reported stronger-than-expected third-quarter results, with adjusted earnings per share rising to $3.00. However, the outlook for lower instrument revenue per procedure and a one-time legal charge overshadowed demand for its robotic surgery systems.
Intuitive Surgical’s third-quarter earnings release, published after Tuesday’s market close, showed revenue climbed 22% year over year to $3.05 billion. Analysts had expected approximately $2.91 billion in revenue and adjusted earnings of $2.65 per share.
Despite the beat, ISRG shares fell nearly 8% in premarket trading on Wednesday, October 21, before recovering part of their losses during the regular session. The stock closed at $427.71, down about 2.4% from the previous close of $438.
The selloff reflected concerns that the quarter’s strong demand could be accompanied by lower revenue per procedure in the future. A newly disclosed $450 million settlement charge reduced reported profit, while management’s plans to lower certain instrument prices raised questions about the company’s recurring revenue stream.
Why ISRG Stock Fell Despite the Earnings Beat
The most immediate financial impact came from an antitrust settlement involving Intuitive’s da Vinci surgical system. The company agreed to pay $450 million to resolve a previously disclosed class-action lawsuit alleging anticompetitive practices. Intuitive denied wrongdoing and said the agreement included no admission of liability. The settlement remains subject to preliminary and final court approval.
Intuitive recorded the full pre-tax charge in the third quarter. After tax, the expense amounted to $347 million, or $0.99 per diluted share.
That cost caused GAAP net income attributable to shareholders to fall to $523 million, or $1.49 per share, from $704 million, or $1.95 per share, a year earlier. The contrast between reported and adjusted results was significant: non-GAAP earnings rose to $1.05 billion, or $3.00 per share, from $867 million, or $2.40 per share, in the prior-year quarter.
The legal expense is a one-time charge rather than a recurring operating cost. However, investors also had to evaluate a separate issue with a longer-term earnings impact: planned pricing changes for surgical instruments and accessories.
During its earnings call, management said the changes could reduce da Vinci instrument and accessory revenue per procedure by approximately 3% to 5% on a mix-constant basis once fully implemented in 2027. The changes include an extended-use instrument program in the US and a price reduction in China beginning in November.
Instruments and accessories generated $1.80 billion in quarterly revenue, up 18% from a year earlier. They are an important part of Intuitive’s recurring business because hospitals purchase these products as they use its surgical systems. Lower revenue per procedure could therefore weigh on growth in this segment, although higher procedure volumes, product mix and adoption of newer systems may offset some of the pressure.
The company says the pricing changes are intended to broaden adoption in high-volume procedures. The market concern is whether increased use will be sufficient to compensate for the lower revenue generated per procedure.
What Intuitive Surgical’s Outlook Means for Investors
Intuitive’s operating performance remained strong in the quarter. Procedures performed using its da Vinci and Ion platforms grew approximately 15% worldwide. Da Vinci procedures increased 14%, while Ion procedures, used in robotic-assisted lung biopsy, rose 31%.
The company placed 546 da Vinci surgical systems during the quarter, compared with 427 a year earlier. That total included 315 of its newer da Vinci 5 systems, up from 240 in the third quarter of 2025. Its installed base of da Vinci systems reached 12,094 at the end of September, a 12% increase from a year earlier.
Those figures point to continued demand for robotic-assisted surgery. Yet management expects 2026 worldwide da Vinci procedure growth of approximately 14% to 15% and said it expects to finish closer to the midpoint of that range. The guidance is narrower than the previous 13.5% to 15.5% range and removes some of the upside investors may have hoped to see.
Margins are another consideration. Intuitive expects its 2026 non-GAAP gross profit margin to be between 68.7% and 69.3%. The range includes an estimated tariff impact equal to 0.9% of revenue, assuming the tariffs in effect when the guidance was issued remain in place through the end of the year. The company also expects non-GAAP operating expenses to grow 11% to 13% in 2026.
The combination of pricing changes and tariff costs gives investors more reason to scrutinize profitability even when revenue is growing. A similar divide between headline earnings and market expectations appeared when Johnson & Johnson reported its third-quarter results, as investors weighed strong underlying performance against litigation costs and uneven medical-technology growth.
Valuation is also relevant. Investors often pay a premium for medical technology companies when they expect sustained growth, but that can leave share prices vulnerable when forecasts become less certain. The performance of healthcare stocks that have outperformed the wider market shows that the sector’s performance has varied widely by company and business model.
For ISRG shareholders, the latest quarter presents a mixed picture. Intuitive beat consensus estimates and expanded its installed base, but its legal settlement reduced reported earnings and planned pricing changes could constrain recurring revenue per procedure. Investors will be watching how procedure growth, system placements and margins develop as the company rolls out those changes.
The stock’s decline does not necessarily indicate that demand for robotic surgery is weakening. Rather, the market is reassessing how future growth translates into earnings. The next test will be whether Intuitive can broaden adoption enough to offset lower instrument pricing while maintaining the profitability that has supported its valuation.